# A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma

> **NCT06670105** · PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- B-cell Lymphoma

## Interventions

- **DRUG:** Glofitamab

## Key facts

- **NCT ID:** NCT06670105
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-06-06
- **Primary completion:** 2030-01-06
- **Final completion:** 2032-01-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI Request
- **Last updated:** 2025-09-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06670105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06670105, "A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06670105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*